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Receptor-mediated increase in cytosolic calcium in LLC-PK1 cells by
platelet activating factor and thromboxane A2. Several studies indicate
an important role of platelet activating factor (PAF) and thromboxane
A2 (TXA2) in glomerular pathophysiology. However, the potential role
of PAF or TXA2 in renal tubular pathophysiology has received little
attention, and the presence of functional receptors for these autacoids
in renal tubular epithelium has not been previously studied. We
examined the effects of PAF and the TXA2 analogue, ONOl 1113, on
the cytosolic free calcium concentration ([Ca241) in cultured LLC-PK!
cell line using a fluorescent probe, fura-2. In these cells, the addition of
PAF or ONOllll3 caused a significant increment in FCa2I1 in a
dose-dependent manner: both agonists (l0 M) increased [Ca2] from
148 16 to 288 39 nM and from 130 8 to 240 18 n, with the
values of EC50 for PAF and ONOI 1113 being 17 4 and 17 2 nrvi,
respectively. These effects were both rapid and transient, returning to
baseline in two minutes. The effect of PAF was selectively blocked by
PAF receptor antagonist BN50730, but not by TXA2 receptor antago-
nist L657925. Similarly ONOI 1113 response was abolished by L657925,
but not by BN50730. PAF- or ONOllIl3-challenged cells did not
respond to a second addition of the same agent and showed heterolo-
gous desensitization to the other agonist. The initial peaks of [Ca2] as
well as the sustained elevations in [Ca2I1 induced by PAF or
ONO1 1113 were reduced following the chelation of extracellular Ca2
by 10 m ethylene glycol-bis(f3-aminomethyl ether)-N,N,N',N'-tet-
raacetic acid (EGTA). In the absence of extracellular Ca2 8-(N,N-
dimethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride (TMB-8)(which has extensively been used to study the contribution of Ca2
released from intracellular storage sites in the increase in [Ca2iJ,
blocked the increment in [Ca2] induced by PAF or ONO 11113. These
results indicate that LLC-PKI cells express discrete receptors for PAF
and TXA2 that are coupled to an increase in [Ca2J through mobiliza-
tion of calcium from both intracellular storage sites and extracellular
milieu, and suggest the possible importance of PAF and TXA2 in
tubular pathophysiology.
A large body of in vitro and in vivo studies have delineated an
important role of two endogenously generated lipids, platelet
activating factor (PAF, I -O-alkyl-2-acetyl-sn-glyceryl-3-phos-
phorylcholdine) and thromboxane A2 (TXA2) in a variety of
inflammatory processes [1—9]. PAF or TXA2, which can be
generated by either bone marrow derived cells or resident
glomerular cells, have been shown to affect a variety of biolog-
ical processes of potential importance in the pathophysiology of
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glomerular disease [1—7, 9, 10]. Not only are some of the
biological effects of PAF and TXA2 similar [1, 5, 6, 10, 11], but
both in vivo and in vitro studies have demonstrated interactions
between these mediators [1, 7—10]; for example, PAF is also
capable of stimulating the biosynthesis of TXA2 from mesangial
cells or other renal tissue [1, 7, 8, 10]. In vivo studies have also
implicated these autacoids in several models of glomerular
injury, including adriamycin-induced nephrotic syndrome [6],
acute serum sickness [2], and anti-GBM antibody disease [12].
Taken together, these studies indicate an important role of
these mediators in glomerular pathophysiology. However, the
potential role of PAF or TXA2 in renal tubular pathophysiology
has received little attention, and the presence of functional
receptors for these autacoids in renal tubular epithelium has not
been previously studied.
Based on the potential importance of intracellular calcium as
second messenger modulating cellular function of tubules [13—
19j and its possible importance in tubular injury [20], as well as
the ability of PAF [21—28] or TXA2 [29—32] to increase intra-
cellular cytosolic free calcium ([Ca2i) in other tissues, the
present studies were undertaken to determine the effects of
PAF and a stable TXA2 analogue, ONO 11113, on [Ca2] in the
LLC-PK1 cell line. LLC-PK1 cells, a widely studied, estab-
lished cell line with some transport characteristics of proximal
tubule [33], have been shown in several recent studies to be
useful for studying cellular calcium metabolism [34, 35]. We
also examined whether the effects of PAF or TXA2 were
receptor mediated, using selective receptor antagonists for PAF
[36] or for TXA2 [11].
Methods
Culture condition
LLC-PK1 cells were obtained from the American Type
Culture Collection (ATCC, Rockville, Maryland, USA). Cells
were regularly grown in 75 cm2 polystyrene tissue culture flasks
(Corning Glass Works, Corning, New York, USA) and main-
tained in a medium composed of Dulbeco's modified Eagle's
medium (DMEM; Gibco Laboratories, Grand Island, New
York, USA), 10% heat-inactivated bovine serum (FBS), 20 mM
N-2 hydroxyethylpiperazine-N'-2-ethanesulfonic acid
(HEPES), 2 mivi L-gluthamine, and 2 mi non-essential amino
acids. Cultures were maintained in a humidified incubator
gassed with 5% C02-95% air at 37°C, and fed at intervals of 48
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to 72 hours. Experiments were performed two to three days
post-confluency. Medium was changed 12 to 24 hours before
experiments. Experiments were performed on passages be-
tween 200 and 220.
Intracellular free calcium concentration measurement
Cells were harvested by trypsinization (for 5 to 10 mm) with
0.05% trypsin and 0.53 mi EDTA (Gibco). The treatment of the
cells with trypsinization for a short term period has been shown
not to affect the total cellular Ca2 content in LLC-PK1 cells
[34]. Isolated cells were washed in a modified Gey's buffer
(MGB; composition in mi: 145.0 NaCI, 5.0 KC1, 1.0 Na2HPO4,
10.0 HEPES, 5.0 glucose, 1.0 CaCI2, 0.5 MgSO4, adjusted pH
to 7.40) by centrifugation for five minutes at 200 x g and
resuspended in 10 ml MGB. Cells were incubated with 4 M
fura-2-AM diluted in dimethyl sulfoxide (0.4% final DMSO
concentration) for 30 minutes, at 37°C. Cells were then washed
three times and resuspended in the MGB to a concentration of
1 x 106 cells/mI. Cell viability after loading fura-2 and at the end
of the experiments was assessed by trypan blue exclusion, and
exceeded 95%.
Intracellular fura-2 fluorescence was monitored using a LS-5
Fluorescence Spectrophotometer (Perkin-Elmer, Norwalk,
Connecticut, USA) with 340 nm excitation (slit width 5 nm) and
500 nm emission (slit width 5 nm). Measurements were made on
continuously stirred 1.2 ml cell suspensions maintained at 37°C
by a circulating water jacket. Fluorescence measured after the
addition of 50 M digitonin defined the maximum fluorescence
(Fmax), and subsequent addition of 10 ms'i Tris base and 10mM
EGTA defined the minimum fluorescence (Fmin). We confirmed
that the fluorescence reached after addition of either high
concentrations of ionomycin (30 jiM) or 0.5% Triton X-100 were
identical to those attained when cells were permealized with 50
jiM digitonin. The fall in fluorescence following 10 mrvi EGTA
added to a fresh sample of cells before each experiment was
used to determine background fluorescence due to extracellular
fura-2 and was used to correct the responses (cF). Cytosolic
free calcium, [Ca2]1, was calculated from the following equa-
tion:
[Ca2 + = Kd[(cFobs — Fmin)/(Fma x — cFobs)]
The Kd value of fura-2 for Ca2 has been determined to be 224
flM [37].
To improve an assessment and accuracy of calcium concen-
tration measurement using fura-2AM, the following was ad-
dressed. We determined whether the fura-2-loaded cells were
de-esterified completely after loading by the method of High-
smith, Bloebaum and Snowdowne [38]. Cells were incubated
with fura-2AM (1 jiM) using either Ca2 free (with 1 mM EGTA)
or Ca2 replete MGB (Ca2 1 mM) for 30, 60 and 90 minutes,
then washed and resuspended in the same buffer. The cell
suspensions were lysed with 0.5% Triton X-100 and centrifuged
at 200 x g. Then the supernatants were monitored at excitation
between 310 and 410 nm with 510 nm emission. These spectra
were compared with the spectra obtained by the fura-2 free acid
solution (1 jiM) in the same Ca2 free or Ca2 replete MGB.
The spectra of the supernatant at the time indicated after
loading with fura-2AM was identical completely to that attained
by the fura-2 free acid solution, suggesting virtually complete
deesterification of fura-2AM in LLC-PK1 cells in our experi-
ments. Since fura-2AM can be hydrolyzed in mitochondria as
well as cytosol [39. 40], the predominant cytosolic localization
of fura-2 providing a Ca2-sensitive signal in our experiments
was established as previously described [40]. In brief, the fura-2
loaded cells were resuspended and incubated for five minutes in
the MGB containing 1 jiM Ca2 and 1.3 jiM rhodamine 123, then
20 jiM digitonin was added until the leakage of cytosolic fura-2
was complete. The cell suspension was washed and resus-
pended in the same MGB except for absence of rhodamine,
followed by observation of the cells for rhodamine 123 local-
ization at 490 nm excitation, 520 nm emission. The cells treated
in this fashion accumulated and retained rhodamine in their
mitochondria, but no signal of fura-2 from a compartment of
mitochondria was retained. This indicated no significant mito-
chondrial contribution to the Ca2-sensitive fura-2 signal of
LLC-PK1 cells in our experiments since I jiM Ca2 should be
enough to retain a mitochondrial potential [41]. Furthermore, a
photobleaching was not evident until at least 30 minutes after
the exposure of a xenon light (slit width 5 nm) to fura-2 free acid
solution in the Ca2 free and Ca2 replete MGB by monitoring
the intensity and spectra of fura-2 emission when excited at 340
nm with 510 nm emission as previously described [42]. To
calibrate the rate of fura-2 leakage, MnCI2 (0.1 mM) was added
to the cell suspensions in Ca2 replete MGB (Ca2 1 mM),
followed by the addition of diethylenetriaminepentaacetic acid
(DTPA, 0.2 mM) as previously described [24, 39]. Under the
condition of our experiments, the leakage of fura-2, 60 minutes
after loading, represented approximately 10% of the total cel-
lular fluorescence. In addition, the magnitude of quenching
extracellular and/or leakage of fura-2 by 0.1 mr.t MnCI, was
identical to that obtained by addition of 10 mri EGTA. How-
ever, to minimize fura-2 leakage, cells were used immediately
after loading and discarded within one hour.
Reagents
PAF (L-a-phosphatidylcholine, /3-acetyl-y-O-hexadecyl) was
obtained from Sigma Chemical Co. (St. Louis, Missouri, USA).
The stable TXA2 analogue, ONO 11113 (9,1 l-epithio- 11,12-
methano-thromboxane A2) was obtained from Ono Pharmaceu-
tical Co. (Osaka, Japan). The PAF antagonist, BN50730, was
obtained from Dr. Braquet (Institute Henri Beaufour, Le
Plessis-Robinson, France), and TXA2 receptor antagonist,
L657925, was obtained from Merk-Frosst, Canada. 8-(N,N-
dimethylamino)octyl 3 ,4,5-trimethoxybenzoate hydrochloride
(TMB-8) was purchased from Aldrich Chemical Co. (Milwau-
kee, Wisconsin, USA). Fura-2, fura-2 AM and ionomycin were
purchased from Calbiochem Co. (San Diego, California, USA).
All other chemicals used were obtained from Sigma Chemical
Co. and were of the highest commercial grade available.
Statistics
Results are expressed as means The EC50 was defined
as the concentration of agonist producing half-maximal re-
sponse. EC50 values were determined by a log-logit transfor-
mation of the concentration-response curve. Statistical differ-
ences were determined using the paired t-test. A P value of less
than 0.05 was considered statistically different.
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Results
L657925(1 M) PAF(25nM)
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PAF- and TXA2-stimulated increase in [Ca2 7I
A specific molecular species of PAF was utilized in the
studies. PAF or the TXA2 mimetic, ONO1 1113, elicited a
concentration-dependent increase in [Ca211. Both PAF and
0N011113 at l0 M elicited a small elevation in [Ca2]1 and a
maximum response achieved at l0 M of each agonist. Higher
concentrations of these compounds had no additional effects.
PAF or ONO1 1113 at the concentration of l0— M increased
[Ca2]1 from 148 16 to 288 39 flM (N = 8) and from 130
8 to 240 18 ni (N 7), respectively. Concentration-response
curves (Fig. 1) yielded EC50 values for PAF and ONO1 1113 of
17 4 n and 17 2 nM, respectively (N = 4).
PAF and TXA2 interact with discrete receptors
To examine whether the increases in [Ca2'11 in response to
PAF or TXA2 mimetic, ONO1 1113, were mediated through
activation of discrete receptors, test samples were incubated for
two minutes with either the PAF receptor antagonist, BN50730
[361, or the TXA2/PGH2 receptor antagonist, L657925 [11],
prior to the addition of agonist. BN50730 (1 ILM) completely
inhibited the response to PAF (25 nM) but had no effect on the
response to 0N011113 (25 nM). L657925 (1 .tM) completely
inhibited the response to ONO1 1113 (25 nM) but had no effect
on the response to PAF (25 nM). A representative (of 3
Fig. 2. Selective inhibition of PAF- or 0N011113-
evoked increase in cytosolic free Ca2 with either PAF
antagonist, BN50730, or TXA2 receptor antagonist,
L657925. A suspension of fura-2 loaded cells was
assayed in modified Gey's buffer (Ca2 1 mM). Top:
Cells were challenged with 25 nM PAF 2 mm after
exposure to I /.LM BN50730 (left), or 1 ISM L657925
(right). Bottom: Cells were challenged with 25 nM
ONOI 1113 2 mm after exposure to the same
concentration of BN50730 (left), or L657925 (right).
Tracings are representative of three experiments.
experiments) set of tracings is presented in Figure 2. Taken
together, these data indicate that PAF and TXA2 stimulate the
increase in [Ca2]1 via discrete receptors.
The responses to PAF or ONOllll3 were rapidly desensi-
tized. At maximum concentration of each agonist (100 nM), a
second exposure to the same agonist after the fCa2J1 returned
to baseline, failed to elicit a second response (N = 5, Fig. 3).
This desensitization of repeated agonist stimulation was also
seen even at submaximal concentrations (data not shown). On
the other hand, prior exposure to PAF or ONO1 1113 resulted in
heterologous desensitization of the other agonist. At maximum
concentration of each agonist (100 nM), a second exposure to
other agonist after the [Ca2} returned to baseline, also failed
to elicit a second response (N = 3, Fig. 3). However, after
exposure to 25 nM ONOllll3, the addition of 25 nti PAF to the
same sample elicited 54 17% of the PAF control response (N
= 3), and prior exposure to 25 nM PAF followed by 25 nM
ONO 11113 resulted in 55 15% of the ONO 11113 control
response (N = 4).
Contribution of extracellular calcium to the increase in
[Ca2 induced by PAF and TXA2
To establish the contribution of influx of extracellular Ca2 to
the maximum increase in [Ca2], responses to PAF (100 nM) or
ONOllll3 (100 nM) were elicited in the absence and presence
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Fig. 1. Concentration dependent effect of PAF and
ONOJ 1113 on the increase in cytosolic free Ca2.
Fura-2 loaded cells were suspended in modified
Gey's buffer (Ca2 1 mM) as described under
Methods. Values are mean SEM, N = 4. EC50
values for PAF and ONOllll3 are 17 4 nt and 17
10 100 1000 2 nM, respectively. EC50 values are determined by
a log-logit transformation of the concentration-
ONO 11113, nM response curve.
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Table 1. Effect of extracellular calcium on basal and maximum
increase in tCa2] induced by PAF and ONOI 1113
Basal
[Ca2]
Maximum
[Ca21 tCa2]1
flM
PAF (100 flM, N = 5)
Extracellular Ca2 +
Extracellular Ca2 —
ONOllll3 (100 n, N =
Extracellular Ca2+
Extracellular Ca2—
3)
158 16
123 l4
125 8
94 2
328 50
198 21b
225 18
137 3b
170 42
71 10b
100 10
48 4b
of 10mM EGTA (to chelate extracellular Ca2; Table 1). In the
presence of EGTA, the basal [Ca2I1 in each experiment was
stable at least during the period of observation (data not
shown), and the maximum response to PAF and 0N011113
was reduced to 51 8% (N = 5) and 53 11% (N =3) of that
in the absence of EGTA, respectively. In the presence or
absence of extracellular Ca2 both agonists elicited a rapid
increase in [Ca2]1 that peaked at —20 seconds. In the presence
of extracellular Ca2 the initial peak of [Ca2]1 induced by both
agonists was followed by a slow decay towards baseline with
the sustained elevation at 1.5 to 2 minutes. In the absence of
extracellular Ca2, the response was less sustained than that in
the presence of Ca2 and the return toward baseline was more
rapid and complete (—1 mm). Verapamil (l0— M), a Ca2
channel blocker, failed to block the response induced by PAF
or ONO1 1113 in the presence of extracellular Ca2 even when
cells were exposed to the agent for up to 15 minutes (N = 3;
data not shown).
Effect of TMB-8 on release of intracellular calcium
TMB-8 has been used as a tool to investigate agonist-
stimulated release of intracellular Ca2 in other cell types.
Although its mechanism and exact site of action are poorly
understood, TMB-8 has been shown to block calcium efflux
from intracellular organelles in a variety of cellular responses
[32, 43, 44]. To investigate the contribution to the overall
increase in [Ca2], made by release from intracellular stores,
LLC-PK1 cells were incubated with TMB-8 (l0— M) for 10 mm
prior to the addition of PAF or ONO 11113 utilizing a dose from
the previous study [32]. In the presence of 10 mri EGTA
chelating extracellular Ca2, TMB-8 blocked the PAF (25
nM)-induced increase in [Ca2]1 by 92 5% (N =6, P  0.0005)
and ONO1 1113 (25 nM)-induced increase in [Ca2]1 by 99 1%
(N = 3, P 0.0005) as compared to controls (Fig. 4). The data
strongly suggest that PAF and TXA2 stimulate the release of
Ca2 from intracellular storage sites.
Discussion
The present study demonstrates that LLC-PK1 cells express
discrete receptors for PAF and TXA2 that are functionally
coupled to an increase in [Ca2]1, The presence of functional
receptors for these autacoids has not been previously reported
in renal tubular epithelial cells. The rapid increase in [Ca2i
that we observed with these compounds (—20 seconds) is
similar to the time response that has been obtained with
vasopressin in LLC-PK1 cells [35] and prostaglandins E1 and E2
in MDCK cells [321. The increase in [Ca2] that we observed
with PAF or ONO 11113 is lower than that with vasopressin in
LLC-PK1 cells [35], but similar to that with prostaglandins E1
and E2 in MDCK cells [32].
The EC50 value of PAF (17 nM) for [Ca2] in LLC-PK1 cells
is higher than that determined in macrophage (0.4 nM) [281, but
it is comparable to that in human platelets (10 nM) [21] and the
circulating PAF level (4 to 12 nM) in experimental models of
serum sickness and immunoglobulin E-induced anaphylaxis in
rabbits [2, 3]. The EC50 value of ONO1 1113 in our study (17 nM)
is similar to that in human platelets (18 nM) [11]. Although the
EC50 value of this compound in other cell types is not known,
Altin and Bygrave found that the maximal increment in [Ca2]1
was induced at 20 nri ONOlllI3 in rat liver cells [31], and
+
0
PAF (100 riM)
I
Fig. 3. Desensitization of PAF- and 0N011113-evoked
increase in cytosolic free Ca2. Left panel: A second
exposure to the same agonist after the cytosolic free
Ca2 returned to baseline failed to elicit a second
response even at maximum concentrations (each 100
nM). Right panel: At maximum concentration of PAF
and ONOI 1113 (100 nM), a second exposure to other
agonist after the cytosolic Ca2 returned to baseline,
also failed to elicit a second response. Tracings are
representative of three to five experiments.
Data are expressed as means SEM.
a P 0.005, and b p 0.025, when compared with the samples in the
presence of extracellular Ca2 (1 mM); extracellular Ca2 was chelated
by addition of 10 mii EGTA to a cell suspension.
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Fig. 4. Blockade by TMB-8 of PA F- and 0N011113-elicited increase in
cytosolic free Ca2. In the presence of 10 mM EGTA, chelating
extracellular Ca2 cells were exposed to 25 nM PAF (top) or 25 nM
ONOl 1113 (bottom) in the absence (left) or 10 mm after addition of
10 M TMB-8 (right). TMB-8 was diluted in the same buffer and added
to the cell suspension. Tracings are representative of three to six
experiments.
Mene Ct a! reported, using structurally different TXA2 ana-
logue, U-46619, that this compound ranging from 10 nM to 1 LM
induced [Ca2] increment in a dose-dependent manner in rat
and human mesangial cells [29].
Both PAF and 0N011113 evoked an increment in [Ca2]1
even in the absence of extracellular Ca2, indicating that at
least part of the increase in [Ca2]1 is due to release from
intracellular storage sites. The contribution of intracellular
storage sites is further supported by the ability of TMB-8 (10—a
M), which has extensively been used to study the contribution
of Ca2 released from intracellular storage sites in the increase
in [Ca211 [32, 43, 44] to block almost completely the PAF- or
0N011113-induced increment in [Ca2]1 in the absence of
extracellular Ca2t In addition, our data indicate an important
contribution of extracellular Ca2 and plasma membrane-bound
Ca2 pools to PAF- or ONOI 1113-induced increase in [Ca2]1.
At maximum response, the increase in [Ca2]1 in the presence
of extracellular Ca2 is approximately twice of that achieved
when extracellular Ca2 is chelated with EGTA. The basal
[Ca2]1 after the addition of EGTA was stable, and the baseline
after cellular activation induced by PAF or TXA2 in the
presence of EGTA was the same as that before the addition of
these agonists. The lower basal [Ca211 induced by EGTA
represents the new baseline achieved after extracellular Ca2
was chelated as previously described [32]. In addition, the
increase in [Ca2]1 was not affected by verapamil, suggesting a
verapamil-sensitive Ca2 channel is not mediating the influx.
Taken together, these results indicate that the increment in
[Ca2I1 induced by PAF or 0N011113 is derived from both
intracellular storage sites and influenced by entry of calcium
from the extracellular milieu.
The selective PAF antagonist, BN50730 (1 LM) [36], com-
pletely abolished PAF-induced increment in [Ca2]1, but failed
to affect ONOllll3-induced increment in [Ca2]. In contrast,
the potent TXA2 receptor antagonist, L657925 (1 LM) [11],
selectively abolished ONO 11113-evoked transient increment in
[Ca2]1, but did not affect the PAF-induced increment in
[Ca2]1. In addition, the PAF- or ONO1 1113-challenged cells
were not responsive to a second bolus of the same agent. These
observations demonstrating agonist-specific effect on calcium
homeostasis in LLC-PK1 cells as well as showing PAF- and
ONO1 1113-induced desensitization indicate that LLC-PK1 cells
have the discrete receptors for PAF and TXA2 and that the
increment in [Ca2]1 induced by both agonists are receptor-
mediated phenomenon. Previous in vivo study has demon-
strated that a selective TXA2 antagonist ameliorates the biolog-
ical effects of PAF and that the PAF effects are mediated by
TXA2 in both glomeruli and tubules [9]. Other investigators
have shown that PAF stimulates phospholipase A2, resulting in
the formation of a variety of cyclooxygenase products including
TXA2 metabolites [1, 7, 8]. Our conclusion that LLC-PK1 cells
possess the two different receptors for PAP and TXA2, how-
ever. does not exclude these interelations of the two com-
pounds for their biological effects through discrete receptors.
Although we did not examine the mechanisms by which PAP
or TXA2 mobilize [Ca2]1 in LLC-PK1 cells, based on previous
studies, it appears likely that PAF- and TXA2-induced increase
in [Ca2]1 in LLC-PK1 cells is mediated by the generation of 1P3
[26, 30, 31, 45] and mobilization of Ca2 from intracellular
stores particularly endoplasmic reticulum [26, 34, 45, 46]. In
addition, despite the presence of discrete receptors for PAP and
the TXA2 mimetic, ONO1 1113, the cross-desensitization of the
response to release intracellular Ca2 (similar to that with
vasopressin and its analogues in LLC-PK1 cells [35]) and the
release of Ca2 from TMB-8 sensitive sites by both agents
suggest a common pathway and/or pool of Ca2 release induced
by PAF and TXA2.
It appears that PAF is not usually synthesized in renal tubular
cells [47], and it has been inconclusive whether LLC-PK1 cells
have the capacity for synthesis of prostaglandins [48, 49].
However, in response to various stimuli PAF or TXA2 can be
generated by isolated glomeruli, mesangial cells, as well as bone
marrow-derived cells including platelets, monocytes, macro-
phages, and polymorphonuclear cells [1, 5], which can often be
seen in a variety of glomerular and tubulointerstitial diseases.
Thus, the exposure of renal tubular cells to PAF or TXA2
generated in the microenvironment may cause the rapid in-
crease in [Ca2], resulting in alterations of physiologic and
inflammatory processes in renal tubular cells.
Previous studies have suggested the importance of intracel-
lular calcium as second messenger modulating cellular function
of tubules [13—19] and its possible importance in tubular injury
[20]. The rise in intracellular Ca2 mediates in a variety of renal
tubular cell function including transport of water, salt and
glucose [14, 16, 17] and bicarbonate absorption [15] as well as
cell volume regulation [18, 19]. Hebert, Jacobson and Breyer
have recently shown that prostaglandin E2 inhibits sodium
transport through increase in intracellular Ca2 in rabbit corti-
cal collecting duct [17]. These observations provide at least
some evidence that the intracellular concentration of Ca2
plays a key role in tubular cell function. Although the precise
PAF (25 riM) PAF (25 flM)
C-)
C-
Ci
100 —
50 —
100—
50 —
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pathophysiological significance of PAF- or TXA2-induced in-
crease in intracellular Ca2 in tubular cells remains to be
determined, the ability of these autacoids to increase intracel-
lular Ca2, suggests an important role for these autacoids in
tubular pathophysiology.
In summary, the present study demonstrates that LLC-PK1
cells express discrete receptors for PAF and TXA2 that are
functionally coupled to an increase in [Ca2]. The increase in
[Ca2]1 in response to either agonist resulted from both the
release of intracellular Ca2 from TMB-8-sensitive sites and the
influx of extracellular Ca2t The presence of receptors for these
autacoids and the ability of these autacoids to increase in
intracellular Ca2 in renal tubular epithelial cells suggest the
potential role of these autacoids in tubular pathophysiology.
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